The stock price of Kintara Therapeutics Inc (NASDAQ: KTRA) has plunged by -9.46 when compared to previous closing price of 0.14, but the company has seen a 25.10% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-04 that Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024.
Is It Worth Investing in Kintara Therapeutics Inc (NASDAQ: KTRA) Right Now?
Company’s 36-month beta value is 0.51.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KTRA is 55.20M, and currently, short sellers hold a 3.98% ratio of that floaft. The average trading volume of KTRA on April 08, 2024 was 14.71M shares.
KTRA’s Market Performance
The stock of Kintara Therapeutics Inc (KTRA) has seen a 25.10% increase in the past week, with a 36.66% rise in the past month, and a -18.74% fall in the past quarter. The volatility ratio for the week is 25.41%, and the volatility levels for the past 30 days are at 13.66% for KTRA. The simple moving average for the past 20 days is 30.02% for KTRA’s stock, with a -93.44% simple moving average for the past 200 days.
KTRA Trading at 21.31% from the 50-Day Moving Average
After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.82% of loss for the given period.
Volatility was left at 13.66%, however, over the last 30 days, the volatility rate increased by 25.41%, as shares surge +37.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.42% upper at present.
During the last 5 trading sessions, KTRA rose by +25.10%, which changed the moving average for the period of 200-days by -96.22% in comparison to the 20-day moving average, which settled at $0.1018. In addition, Kintara Therapeutics Inc saw -23.29% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KTRA
The total capital return value is set at -720.4. Equity return is now at value -329.00, with -179.36 for asset returns.
Currently, EBITDA for the company is -14.75 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
In a nutshell, Kintara Therapeutics Inc (KTRA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
